Literature DB >> 29501528

Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats.

Joshua S Elmore1, Ann M Decker2, Agnieszka Sulima3, Kenner C Rice3, John S Partilla1, Bruce E Blough2, Michael H Baumann4.   

Abstract

2,5-Dimethoxyphenethylamines (2C compounds) are 5-HT2A/2C receptor agonists that induce hallucinogenic effects. N-methoxybenzylation of 2C compounds markedly increases their affinity for 5-HT2A receptors, and two such analogs, 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25C-NBOMe) and 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe), have emerged in recreational drug markets. Here, we investigated the neuropharmacology of 25C-NBOMe and 25I-NBOMe in rats, as compared to their 2C analogs and the prototypical 5-HT2A/2C agonist 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine (DOI). Compounds were tested in vitro using 5-HT2A receptor binding and calcium mobilization assays. For in vivo experiments, 25C-NBOMe (0.01-0.3 mg/kg), 25I-NBOMe (0.01-0.3 mg/kg), 2-(4-chloro-2,5-dimethoxyphenyl)ethanamine (2C-C) (0.1-3.0 mg/kg), 2-(4-iodo-2,5-dimethoxyphenyl)ethanamine (2C-I) (0.1-3.0 mg/kg) and DOI (0.03-1.0 mg/kg) were administered subcutaneously (sc) to male rats, and 5-HT2A-mediated behaviors were assessed. NBOMes displayed higher affinity for 5-HT2A receptors than their 2C counterparts but were substantially weaker in functional assays. 25C-NBOMe and 25I-NBOMe were much more potent at inducing wet dog shakes (WDS) and back muscle contractions (BMC) when compared to 2C-C and 2C-I. Pretreatment with the selective 5-HT2A antagonist (R)-(2,3-dimethoxyphenyl){1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl}methanol (M100907) reversed behaviors produced by all agonists. Interestingly, binding affinities at the 5-HT2A receptor were significantly correlated with potencies to induce BMC but not WDS. Our findings show that NBOMes are highly potent 5-HT2A agonists in rats, similar to effects in mice, and consistent with the reported hallucinogenic effects in human users. This article is part of the Special Issue entitled 'Psychedelics: New Doors, Altered Perceptions'. Published by Elsevier Ltd.

Entities:  

Keywords:  5-HT(2A) receptor; Back muscle contractions; NBOMe; Wet dog shakes

Mesh:

Substances:

Year:  2018        PMID: 29501528      PMCID: PMC6119551          DOI: 10.1016/j.neuropharm.2018.02.033

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  35 in total

1.  "My friend said it was good LSD": a suicide attempt following analytically confirmed 25I-NBOMe ingestion.

Authors:  Joji Suzuki; Justin L Poklis; Alphonse Poklis
Journal:  J Psychoactive Drugs       Date:  2014 Nov-Dec

2.  Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs).

Authors:  Anna Rickli; Dino Luethi; Julian Reinisch; Danièle Buchy; Marius C Hoener; Matthias E Liechti
Journal:  Neuropharmacology       Date:  2015-08-25       Impact factor: 5.250

3.  Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists.

Authors:  Michael R Braden; Jason C Parrish; John C Naylor; David E Nichols
Journal:  Mol Pharmacol       Date:  2006-09-25       Impact factor: 4.436

4.  Schedules of controlled substances: temporary placement of three synthetic phenethylamines into Schedule I. Final order.

Authors: 
Journal:  Fed Regist       Date:  2013-11-15

5.  "Wet-dog" shake behaviour in the rat: a possible quantitative model of central 5-hydroxytryptamine activity.

Authors:  P Bedard; C J Pycock
Journal:  Neuropharmacology       Date:  1977-10       Impact factor: 5.250

6.  A possible correlation between drug-induced hallucinations in man and a behavioural response in mice.

Authors:  S J Corne; R W Pickering
Journal:  Psychopharmacologia       Date:  1967

7.  Chronic cocaine exposure potentiates prolactin and head shake responses to 5-HT2 receptor stimulation in rats.

Authors:  M H Baumann; R B Rothman
Journal:  Neuropharmacology       Date:  1996-03       Impact factor: 5.250

8.  Influence of amine substituents on 5-HT2A versus 5-HT2C binding of phenylalkyl- and indolylalkylamines.

Authors:  R A Glennon; M Dukat; M el-Bermawy; H Law; J De los Angeles; M Teitler; A King; K Herrick-Davis
Journal:  J Med Chem       Date:  1994-06-24       Impact factor: 7.446

9.  25C-NBOMe--new potent hallucinogenic substance identified on the drug market.

Authors:  Dariusz Zuba; Karolina Sekuła; Agnieszka Buczek
Journal:  Forensic Sci Int       Date:  2012-09-16       Impact factor: 2.395

10.  Correlating the metabolic stability of psychedelic 5-HT₂A agonists with anecdotal reports of human oral bioavailability.

Authors:  Sebastian Leth-Petersen; Christoffer Bundgaard; Martin Hansen; Martin A Carnerup; Jan Kehler; Jesper Langgaard Kristensen
Journal:  Neurochem Res       Date:  2014-02-12       Impact factor: 3.996

View more
  12 in total

1.  Methiopropamine and its acute behavioral effects in mice: is there a gray zone in new psychoactive substances users?

Authors:  Fabio De-Giorgio; Sabrine Bilel; Micaela Tirri; Raffaella Arfè; Claudio Trapella; Cristian Camuto; Federica Foti; Paolo Frisoni; Margherita Neri; Francesco Botrè; Matteo Marti
Journal:  Int J Legal Med       Date:  2020-05-01       Impact factor: 2.686

2.  Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors.

Authors:  Amy J Eshleman; Katherine M Wolfrum; John F Reed; Sunyoung O Kim; Robert A Johnson; Aaron Janowsky
Journal:  Biochem Pharmacol       Date:  2018-09-25       Impact factor: 5.858

3.  New designer phenethylamines 2C-C and 2C-P have abuse potential and induce neurotoxicity in rodents.

Authors:  Young-Jung Kim; Shi-Xun Ma; Kwang-Hyun Hur; Youyoung Lee; Yong-Hyun Ko; Bo-Ram Lee; Seon-Kyung Kim; Su-Jeong Sung; Kyeong-Man Kim; Hyoung-Chun Kim; Seok-Yong Lee; Choon-Gon Jang
Journal:  Arch Toxicol       Date:  2021-01-30       Impact factor: 5.153

4.  Automated Computer Software Assessment of 5-Hydroxytryptamine 2A Receptor-Mediated Head Twitch Responses from Video Recordings of Mice.

Authors:  Grant C Glatfelter; Michael R Chojnacki; Shelby A McGriff; Tianpeng Wang; Michael H Baumann
Journal:  ACS Pharmacol Transl Sci       Date:  2022-04-08

5.  DARK Classics in Chemical Neuroscience: NBOMes.

Authors:  Christian B M Poulie; Anders A Jensen; Adam L Halberstadt; Jesper L Kristensen
Journal:  ACS Chem Neurosci       Date:  2019-11-12       Impact factor: 5.780

6.  Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species.

Authors:  Adam L Halberstadt; Muhammad Chatha; Adam K Klein; Jason Wallach; Simon D Brandt
Journal:  Neuropharmacology       Date:  2020-01-07       Impact factor: 5.273

7.  Neurochemical and Behavioral Effects of a New Hallucinogenic Compound 25B-NBOMe in Rats.

Authors:  Adam Wojtas; Monika Herian; Mateusz Skawski; Małgorzata Sobocińska; Alejandro González-Marín; Karolina Noworyta-Sokołowska; Krystyna Gołembiowska
Journal:  Neurotox Res       Date:  2020-12-18       Impact factor: 3.911

Review 8.  Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans.

Authors:  Paul Cumming; Milan Scheidegger; Dario Dornbierer; Mikael Palner; Boris B Quednow; Chantal Martin-Soelch
Journal:  Molecules       Date:  2021-04-22       Impact factor: 4.411

Review 9.  Designer drugs: mechanism of action and adverse effects.

Authors:  Dino Luethi; Matthias E Liechti
Journal:  Arch Toxicol       Date:  2020-04-06       Impact factor: 5.153

10.  Contribution of serotonin receptor subtypes to hallucinogenic activity of 25I-NBOMe and to its effect on neurotransmission.

Authors:  Monika Herian; Adam Wojtas; Małgorzata Katarzyna Sobocińska; Mateusz Skawski; Alejandro González-Marín; Krystyna Gołembiowska
Journal:  Pharmacol Rep       Date:  2020-11-10       Impact factor: 3.024

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.